Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2024
Spring on the Road
Spring Wellness 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Parcel Pick Up
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics, Inc. - Common Stock
(NQ:
SRPT
)
97.19
-1.18 (-1.20%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sarepta Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases
March 10, 2025
Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be presented at a 2025 medical meeting.
Via
Benzinga
SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) showing high EPS and FCF growth while beating expectations
March 04, 2025
A fundamental analysis of (NASDAQ:SRPT): SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) may be suited for growth investing, we'll explore why in this article.
Via
Chartmill
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
March 04, 2025
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
8 Analysts Have This To Say About Sarepta Therapeutics
February 27, 2025
Via
Benzinga
Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcript
February 26, 2025
SRPT earnings call for the period ending December 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Earnings Scheduled For February 26, 2025
February 26, 2025
Via
Benzinga
2 Growth Stocks to Buy Hand Over Fist in February
February 09, 2025
Via
The Motley Fool
What 14 Analyst Ratings Have To Say About Sarepta Therapeutics
January 15, 2025
Via
Benzinga
A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 15 Analysts
December 19, 2024
Via
Benzinga
Sarepta Therapeutics’s (NASDAQ:SRPT) Q4: Beats On Revenue
February 26, 2025
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) announced better-than-expected revenue in Q4 CY2024, with sales up 65.9% year on year to $658.4 million. Its non-GAAP profit of $1.90 per share was...
Via
StockStory
10 Health Care Stocks Whale Activity In Today's Session
February 26, 2025
Via
Benzinga
Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect
February 25, 2025
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to know.
Via
StockStory
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
February 19, 2025
Solid Biosciences just saw a 32% move to the upside after its trial results impressed. What's next for this firm that analysts still see massive potential in?
Via
MarketBeat
Exposures
Product Safety
Analyst Expectations For Sarepta Therapeutics's Future
November 25, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Sarepta Therapeutics Through Analyst Insights
October 21, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
February 14, 2025
Via
Benzinga
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years
January 27, 2025
Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression.
Via
Benzinga
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development
January 08, 2025
Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting key 2025 milestones.
Via
Benzinga
Exposures
Product Safety
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
December 13, 2024
Wedbush initiates Solid Biosciences with an Outperform rating, citing the potential of SGT-003 for Duchenne muscular dystrophy and a robust cash runway.
Via
Benzinga
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
December 01, 2024
8 mid-cap stocks saw impressive gains last week. Archer, Scholar Rock, Arrowhead, Iris Energy, Hims & Hers, SoundHound, Joby Aviation, and Urban Outfitters all performed well.
Via
Benzinga
Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
December 01, 2024
Top performers last week: RIVN, RKLB, SRPT, EXAS, ESTC, ULTA, MRNA, RL, CPRT, SNAP. Any in your portfolio? Citigroup raises price target on ULTA and SNAP.
Via
Benzinga
Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 30
November 30, 2024
Via
Talk Markets
Topics
Stocks / Equities
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?
November 26, 2024
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics Inc. (NASDAQ: SRPT)....
Via
Benzinga
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
November 26, 2024
Via
Benzinga
Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta
November 26, 2024
The deal focuses on four clinical-stage drugs, three preclinical assets and a potential five new targets.
Via
Investor's Business Daily
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
November 25, 2024
Via
Benzinga
Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
November 07, 2024
Via
Benzinga
This McKesson Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
November 07, 2024
Via
Benzinga
Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript
November 07, 2024
SRPT earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
October 21, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.